Neurofibromatosis type 1 (NF1) is a common tumor-predisposition disorder due to germline mutations in the tumor suppressor gene NF1. A virtually pathognomonic finding of NF1 is the plexiform neurofibroma (PN), a benign, likely congenital tumor that arises from bi-allelic inactivation of NF1. PN can undergo transformation to a malignant peripheral nerve sheath tumor, an aggressive soft-tissue sarcoma. To better understand the non-NF1 genetic contributions to PN pathogenesis, we performed wholeexome sequencing, RNASeq profiling and genome-wide copy-number determination for 23 low-passage Schwann cell cultures established from surgical PN material with matching germline DNA. All resected tumors were derived from routine debulking surgeries. None of the tumors were considered at risk for malignant transformation at the time; for example, there was no pain or rapid growth. Deep (~500X) NF1 exon sequencing was also conducted on tumor DNA. Non-NF1 somatic mutation verification was performed using the Ampliseq/IonTorrent platform. We identified 100% of the germline NF1 mutations and found somatic NF1 inactivation in 74% of the PN. One individual with three PNs had different NF1 somatic mutations in each tumor. The median number of somatic mutations per sample, including NF1, was one (range 0-8). NF1 was the only gene that was recurrently somatically inactivated in multiple tumors. Gene Set Enrichment Analysis of transcriptome-wide tumor RNA sequencing identified five significant (FDR o 0.01) and seven trending (0.01 ⩽ FDRo 0.02) gene sets related to DNA replication, telomere maintenance and elongation, cell cycle progression, signal transduction and cell proliferation. We found no recurrent non-NF1 locus copynumber variation in PN. This is the first multi-sample whole-exome and whole-transcriptome sequencing study of NF1-associated PN. Taken together with concurrent copy-number data, our comprehensive genetic analysis reveals the primacy of NF1 loss as the driver of PN tumorigenesis.
INTRODUCTION
Neurofibromatosis type 1 (NF1) is a common (1/3,000), autosomal dominant, fully penetrant neurocutaneous tumor-predisposition disorder that is caused by mutations in the tumor suppressor gene NF1, located on chromosome 17q11.2. 1 It is diagnosed using well-established clinical criteria 2 that emphasize specific hallmark features including café-au-lait macules, intertriginous freckling, neurofibromas, optic pathway gliomas, and specific bone dysplasias. A virtually pathognomonic finding of NF1 is the plexiform neurofibroma (PN), an often-congenital neurofibroma that affects 30% (when defined clinically 3 ) to 56% (when identified by imaging 4 ) of people with the disorder. Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft-tissue sarcomas with limited therapeutic options that frequently arise from PN. People with NF1 have a lifetime risk of about 15% to develop MPNST. 5, 6 PNs arise from within spinal, cranial and peripheral nerves and typically involve multiple nerve roots or the length of a single nerve and may occur anywhere, although there is a predilection for neck and trunk, at least in those patients enrolling in treatment trials. 7 The growth of PN tends to track with that of the individual, tapering off in late adolescence, although in some patients the growth rate is unpredictable and can be very disfiguring, especially early in childhood. 8 Some PNs may not be diagnosed until adulthood, and thus the timing of the origin is unknown. Prognostication of PN growth for a specific patient is difficult, and no therapies, other than surgery, are effective, despite a number of trials testing novel agents. 9, 10 Clinically, in addition to their contribution to MPNST pathogenesis, PNs are a significant cause of morbidity due to their propensity for local invasion, bone erosion, organ compression, chronic pain and untoward esthetics.
Histologically, PN are similar to solitary neurofibromas and are composed of myxoid stroma and a cellular component. The cellular element is heterogeneous and complex and consists primarily of S-100-positive Schwann cells (60-80%) 11 but also fibroblasts, endothelial cells, perineurial cells, smooth muscle cells, mast cells, residual interspersed axons and pericytes. 12 In neurofibromas, the Schwann cell is the primary neoplastic cell and is the only cell to harbor a 'second hit' in the NF1 gene.
Although it is clear that NF1 nullizygosity in a subset of Schwann cells is critical for PN development, we have limited or conflicting understanding of the other genetic factors that contribute to PN tumorigenesis. From family studies, we know that PN burden is heritable 15 and not associated with the type of germline NF1 mutation 16 or wildtype NF1 allele. 15 The noncoding RNA ANRIL has been proposed as a modifier of PN burden. 17 MPNSTs, unlike PNs, are complex, genetically rearranged tumors that harbor somatic mutations or copy-number changes in TP53, CDKN2A/B, EGFR, mTOR, ERBB2, KIT, HGF, MET, SUZ12 and PDGFRA. [18] [19] [20] [21] One microarray study found the only recurrent somatic alteration in PN were deletions of the CDKN2A/B-ANRIL locus at 9p21.3 in 6/22 tumors. 17 Activation of the WNT signaling pathway may also be a feature of PN and MPNST tumorigenesis. 19 We are aware of only one publication that exome-sequenced a single PN as part of its malignant transformation to a MPNST. 22 To better understand the non-NF1 genetic contributions to PN pathogenesis, we performed whole-exome sequencing, RNASeq profiling and copy-number determination for 23 low-passage Schwann cell cultures established from surgical PN material.
RESULTS
Whole exome-sequencing (WES) of 23 NF1-associated PNs with matching germline DNA resulted in high confidence genotypes (most probable genotype quality score410) in~90% of target nucleotides. The average depth of coverage was 55X and 63X for germline and tumor DNA, respectively (Supplementary Table S1 ).
Identification of germline and somatic mutations in NF1
In addition to WES, we performed deep sequencing (~500X) of the coding part of NF1 in all PNs on the IonTorrent platform. We identified germline NF1 mutations in 100% of the 23 samples (Figure 1, Supplementary Table S2A ). Note that two of the samples were tumors from monozygous twins (PN23 and PN24) and three samples were independent tumors from the same patient obtained at different times (PN25, PN26 and PN28), for a total of 21 independent NF1 germline mutations. Germline mutation type in decreasing order of frequency were: frame-shifting indels (38%), nonsense (33%), splice-site (14%), missense (10%) and a single total gene deletion (5%; Table 1 ). All mutations except two were truncating, affected splice-sites and/or were reported in HGMD as pathogenic. Of the two exceptions, the missense mutation in PN11 (exon21, c.2542G4T, G848W) results in substitution of glycine, the smallest aliphatic amino acid, by tryptophan, a bulky aromatic compound, likely leading to significant modification or inactivation of the protein function. It is also not observed in the ExAC reference of 61,000 exomes. The second exception was a silent substitution in PN19 (exon31, c.4269G4A, p.K1423K). This synonymous missense mutation is not observed in ExAC and results in a cryptic splice site that results in an in-frame loss of 27 bp of coding sequence. Therefore we consider the two 'exceptions' to also be pathogenic germline mutations.
We identified somatic NF1 mutations in 74% of the 23 tumors (Table 1 and Supplementary Table S2B ). There were 7 (30%) large deletions, 6 (26%) nonsense and 2 (9%) frame-shifting variants. We found two somatic NF1 missense mutations (R997K in PN9, and G2481E in PN11) that appear pathogenic because they affect conserved residues and are de novo hits in the NF1 gene with no other apparent pathogenic somatic mutation. Both variants have CADD scores 420 and thus are predicted to be in the top 1% of deleteriousness. 23 Neither of these somatic missense mutations were previously reported in HGMD, COSMIC or ExAC. R997K in PN9 was detected by both WES and IonTorrent sequencing and appears to be present in the majority of tumor cells, while G2481E in PN11 was identified by IonTorrent only and is present only in a small number of cells. Two tumors (PN21 and PN26) showed two Figure 1 . Distribution of germline (upper panel) and somatic (lower panel) NF1 mutations among 23 plexiform neurofibromas. Black and green dots represent truncating (nonsense, frame-shifting indels and splice-site substitutions) and missense mutations, respectively. Green and red rectangles represent the RAS-GAP and CRAL/TRIO (SEC14-like) domains, respectively. Note that germline substitutions K583R and K1423K result in splicing defects and therefore depicted with black dots. The germline nonsense mutation R816X was found in two unrelated individuals, and the germline frame-shifting mutation L2112fs was found in monozygotic twins and was counted for both individuals. Large deletions are not shown on the diagram (for details see Supplementary Tables S2A and B) .
somatic mutations each (a missense variant accompanied by either a nonsense (PN21) or frameshifting (PN26) variant), that were identified by IonTorrent deep sequencing but not WES.
All frame-shifting small indels detected in germline and tumor DNA were novel, whereas the majority of nonsense, and splice-site point substitutions had been previously reported. Germline and somatic missense mutations were both previously reported and novel. Importantly, in the patient with the three different PN (PN25, PN26, PN28), three different second hits in NF1 occurred, suggesting a stochastic random deactivation of the normal copy of the gene, as first proposed by Colman et al.
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NF1 expression in PN and normal schwann cells Compared with normal Schwann cells (100%), median NF1 expression in PN was 53% (range: 16-107%; Figure 2 ). Samples with lower expression values of NF1 (lower half of samples in Figure 2a ) had a higher number of total/partial gene deletions (6 vs 1), as well as frame-shifting indels (8 vs 5) and nonsense mutations (7 vs 5) compared with the samples with higher expression values of the gene. This observation is consistent with the previous findings that nonsense and frame-shifting mutations may trigger some degree of nonsense mediated decay of RNA molecules with multiple stop codons. Interestingly, samples without second hits were found in the upper half of the expression value distribution (Figure 2 ).
NF1 as the sole driver in pathogenesis of plexiform neurofibromas Besides NF1, we identified 26 high-confidence somatic mutations; 19 (73%) were non-synonymous and 15 (58%) were potentially damaging ( 26 or glioblastoma 27, 28 sequencing projects. NF1 was the only gene that was somatically mutated in multiple samples. The lack of recurrent, deleterious mutations in biologically plausible genes suggests that these variants are 'passengers' and not primary drivers of plexiform neurofibromagenesis. The distribution of these 15 non-NF1 putatively-damaging somatic mutations among the 23 PN tumors is shown in Table 3 ; only five tumors (22%) had potentially damaging somatic mutations outside of the NF1 locus. The median number of somatic mutations per sample (including mutations in NF1) was one (range 0-8). Interestingly, only six out of these 15 genes were expressed in the tumors or normal Schwann cells as determined by RNAseq analysis, suggesting that only a minor proportion of mutations could potentially play a role in tumor phenotype. Eight gene sets were up-regulated and four gene-sets were down-regulated in PN compared with normal Schwann cells. There were 300 genes in the 12 sets that contributed to the enrichment score (the leading-edge genes), and 60 genes were found in at least two different gene sets (Supplementary  Table S4 ). Plotting expression of these genes in tumors vs normal Schwann cells revealed that 52 of them found in up-regulated sets were moderately overexpressed and eight genes found in down-regulated sets were under-expressed in tumors ( Figure 4 ).
S t o p / N o t d e t e c t e d S p l i c i n g / F r a m e s h i f t M i s s e n s e / N o t d e t e c t e d S t o p / P G D S p l i c i n g / N o t d e t e c t e d M i s s e n s e / M i s s e n s e F r a m e s h i f t / F r a m e s h i f t F r a m e s h i f t / N o t d e t e c t e d F r a m e s h i f t / N o t d e t e c t e d S t o p / M i s s e n s e S t o p / S t o p T G D / N o t d e t e c t e d F r a m e s h i f t / C N -L O H S t o p / T G D F r a m e s h i f t / S t o p S t o p / P G D F r a m e s h i f t / F r a m e s h i f t F r a m e s h i f t / S t o p S p l i c i n g / S t o p S t o p / S t o p F r a m e s h i f t / T G D
Copy-number analysis identifies no recurrent non-NF1 copy number variations Remarkably, we did not identify a single significant recurrent copy number variation (CNV) outside of the NF1 locus by Nexus analysis. We found copy-neutral loss of heterozygosity (LOH) affecting the entire q-arm of chromosome 17 in a single tumor (PN27) by both ASCAT and Nexus consistent with mitotic recombination; six additional smaller partial or total NF1 deletions were identified with the Nexus algorithm only (Supplementary Table S5 ). The size of the deletions ranged from 66 kb (ten exons in the middle of the NF1 gene) to over 24 Mb (the entire 17q-arm). None of the somatic deletions extended into the 17p arm, where TP53 resides, however, in four tumors the deletion also comprised entire SUZ12, which is frequently inactivated in MPNSTs.
DISCUSSION
This study is the first multi-sample whole-exome and whole transcriptome sequencing analysis of NF1-associated PN. Previous work in PN has focused on their cell of origin and microenvironment, 29 dysregulated pathways, 19 and timing of development. 30 One study of WES of PN, MPNST and associated metastases samples collected from a single patient over 14 years found a very limited number of mutations in the PN samples, none of which overlapped with our findings. No copy-number changes were detected in three PN samples from the single patient. 22 Cytogenetic abnormalities have been identified more frequently in cells derived from PN than from dermal neurofibromas, however no consistent chromosomal regions with abnormal karyotypes have been identified in PN. 31 From this work, we establish that the overall exome mutation rate in PN is very low and comparable with pediatric malignancies. The somatic variants (other than NF1) that were confirmed on a second platform appeared in one sample only and most were not predicted to be significantly pathogenic. Furthermore, the majority were found in genes that were not expressed in the tumors or normal Schwann cells. We found no recurrent copy-number variation in PN outside the NF1 locus. Despite the low number of somatic mutations and CNVs in PN, we observed that expression of 300 genes in several key cellular processes, such as DNA replication initiation and strand elongation, cell cycle progression and telomere maintenance and extension, was perturbed. Taken together, our comprehensive genetic analysis reveals the primacy of NF1 loss as the driver of plexiform neurofibroma tumorigenesis.
We identified germline NF1 mutations in 100% of the samples and a somatic NF1 'second hit' in 74% of PN, a rate that is comparable with previous studies. 32 We deep-sequenced (500X) all NF1 exons and intron-exon boundaries in the PN and therefore it is unlikely that we missed any mutations or short indels in those regions. We also carefully examined NF1 RNA transcripts from PN for evidence of aberrantly spliced species, which may have suggested the presence of deep intronic mutations, but did not find any (data not shown). We acknowledge that the SNP arrays we used have limited resolution and would likely fail to detect Exome and transcriptome sequencing of plexiform neurofibromas A Pemov et al medium-sized (100-1000 bp) deletions; however, such deletions are also difficult to identify by NGS approaches. Furthermore, samples with undetected second hits had relatively high levels of NF1 expression, suggesting that these samples contain a relatively smaller ratio of tumor cells. We posit that the samples with undetected second hits harbor deep intronic and/or mediumsized deletions and occur in PNs with a relatively low proportion of NF1 − / − Schwann cells. The spectrum and distribution of NF1 LOH events and discrete mutations in PN from our study was also comparable with previous work. 32 Independent somatic mutations in NF1 have been reported in individuals with two PN. 33 We found non-NF1 somatic mutations at a very low frequency (Tables 2 and 3) , as predicted for a congenital tumor such as a PN. Given the low mutation rate, we cast a broad net to identify somatic variants but applied a rigorous filtering (overlap) scheme to reduce the number of false positives. We acknowledge that our filtering strategy might increase the false-negative rate and we acknowledge that the modest number of samples limits the power.
The non-NF1 somatic mutations identified (Tables 2 and 3 ) appear in a fraction of the reads, suggesting that the cell harboring the mutation is a clonal derivative. Most of these variants are not pathogenic, as predicted by a variety of bioinformatics methods, and do not reside in known cancer pathways. None of the non-synonymous somatic variants in BRCA1, FGFR1 and RNF43 (known cancer genes) from two tumors ( Table 2 and Supplementary Table S3) were present in the COSMIC database. The rs80356892 missense variant in BRCA1 was heterozygous in the germline that became homozygous in the PN due to a large deletion on chromosome 17, which also affected the NF1 locus. BRCA1 was modestly expressed in the tumor (Supplementary Table S3 ). The variant was originally identified in a Japanese patient who developed a breast cancer at age of 54 years, 34 however subsequent multi-center ClinVar review has deemed it benign (ClinVar variant ID # 54604). The NF1 patient harboring this variant has not developed any tumors other than a PN, however she is only in her mid-20s; the histopathology of her PN was unremarkable. The missense variant in RNF43 in tumor PN9 was predicted to be deleterious, however the gene was not expressed in PNs and the variant likely had no effect on the tumor phenotype. The missense FGFR1 variant in tumor PN9 (P772S) was present in parity with its reference allele (Supplementary Table  S3 ), suggesting that it was acquired by the cell soon after the somatic NF1 hit (Ref/Alt counts = 1039/956, Supplementary Table  S2B ). The gene was modestly expressed in the tumor and the mutant allele was expressed at the same rate as the reference one (Supplementary Table S3 ). FGFR1 is a tyrosine-protein kinase that plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration. It mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP-kinase signaling pathway, as well as the AKT1 signaling pathway. Although FGFR1 P772S was reported to be associated with Kallmann syndrome in an earlier paper, 35 its high prevalence in the ExAC database argues (3.83 × 10 − 3 ) against pathogenicity. The PN9 tumor had a relatively loose extra cellular matrix, but was otherwise unremarkable.
Much of the literature on gene expression profiling in NF1 investigates the transition of PN to MPNST. 36, 37 There are few investigations comparing PN expression with normal Schwann cells. In the most comprehensive to date study, Miller et al. 38 compared primary tissue and primary cell cultures of PN, dermal neurofibroma, and MPNSTs with wild-type Schwann cells using gene expression arrays. They found 2827 distinct transcripts in 1952 unique genes differentially expressed among these groups of samples; dermal neurofibroma and PN did not differ significantly from each other. Unlike previous studies that utilized a microarray approach, we used whole-transcriptome RNA-sequencing data to determine differential expression in PN vs normal Schwann cells. In addition, we used Gene Set Enrichment Analysis, an established analytical method that derives its power by focusing on sets of genes, grouped by their function and biology, rather than employing a single-gene approach, known for having a number of limitations. We found five highly statistically significant (FDR o0.01) and seven trending (0.01 ⩽ FDR o0.02) gene sets with known roles in DNA replication, cell proliferation, cell cycle control and telomere maintenance. One of the beststudied consequences of NF1 inactivation is RAS-mediated hyperactivation of the Ras-MAPK and AKT1-PI3K pathways, which play key roles in cell proliferation and differentiation. 39 The functional connection between NF1 inactivation and telomere maintenance and elongation and is less studied, however it may provide insights into mechanisms of immortalization and genomic instability in the tumors. Comparison of the leading-edge set of 300 genes with the set of 1952 differentially expressed genes from Miller et al. 38 revealed an overlap of 36 genes with a p-value of 0.021.
The majority of published investigations on CNV differences in NF1-associated tumors (with paired germline DNA) have been performed on MPNSTs. The few studies that have investigated PNs found a paucity of such changes and a lack of specific recurrent CNVs. Upadhyaya et al. is a typical example and studied CNVs using the Affymetrix Array 6.0 chip and found 996 copy differences in 15 MPNSTs and 26 copy differences in 5 PNs (both paired analyses); 17 of these changes were in a single sample. 40 The ratio of gains to losses was 24/2. Except for one overlap on chromosome 4 in two patients, there were no recurring or overlapping CNVs. 40 In our study, we did not find any recurrent CNVs outside the NF1 locus. We noticed that the majority of large somatic deletions on 17q comprising the NF1 locus also contained the entire SUZ12 gene. Currently it's unclear if hemizygous deletion of SUZ12 confers any advantage in PN-MPNST transformation.
The limited clinical information available on the PNs is included in the Supplementary Clinical Information file. We emphasize that all tumors in this study were asymptomatic and procured from routine debulking surgeries. They were classified as neurofibromas and were not suspected as pre-malignant or malignant lesions; for PRIM2  LIG1  MCM2  MCM4  MCM5  MCM6  MCM7  POLA1  POLD1  POLD3  POLE  PRIM1  RFC2  RFC4  RPA2  RPA3  DNA2  FEN1  MCM3  POLE2  CDC45  GINS4  ORC2  RUVBL2  DUT  GINS1  GINS2  HIST1H4A  HIST1H4B  HIST1H4C  HIST1H4D  HIST1H4F  HIST1H4H  HIST1H4I  HIST1H4J  HIST1H4K  HIST1H4L  HNRNPD  MAD2L1  NOP56  POLE3  RANBP1  RNASEH2A  RUVBL1  SRSF1  SYNCRIP  TRA2B  USP1  WRAP53  XRCC6  DTX2  MYL9  CXCR7  GBP1  KRT16  OLFML2A  RTP4 example, the tumors were not associated with pain or increased growth. Atypical neurofibroma (ANF) and MPNST often arise within pre-existing PNs 18 and it is difficult to detect these tumors clinically in the early stages. In rare instances, a PN tissue could be intermixed with ANF or MPNST, and when cultured pre-malignant or malignant cells could potentially outgrow the benign ones, however we expect that such scenarios would be relatively infrequent and therefore the effect of such tissue heterogeneity on the results would be limited.
In summary, our data show that initiation of NF1-associated PN, a benign, slowly growing tumor, is driven by somatic inactivation of NF1. We observed three independent somatic NF1 mutations in three PN from the same individual, consistent with a clonal origin. Plexiform neurofibromas harbor a near-zero mutation burden outside of the NF1 locus, and the genomic architecture of the tumors closely resembles that of a normal diploid cell. It appears that inactivation of NF1 is sufficient for PN initiation. A series of additional mutations is likely required for subsequent malignant transformation.
MATERIALS AND METHODS
Samples were collected under the IRB-approved protocol ('Genetic Studies of Neurofibromatosis 1 ' 41-1992) and reviewed by the NIH Office of Human Subjects Research. Twenty-three fresh surgical specimens (2-10 g) were obtained from 21 independent subjects (including one set of identical twins) undergoing PN debulking for cosmetic or functional reasons and not for concern about pain or rapid growth. All non-tumorappearing tissue was trimmed away; the remaining tissue was fresh frozen and processed using standard methods for formalin fixing/paraffin embedding, DNA extraction, total RNA extraction (Trizol, Invitrogen), and dissociation into single cell suspension for Schwann-enriched culture. Germline DNA was obtained from EDTA-blood samples, buccal swabs, or from fibroblast cultures derived from the tumor cultures.
Culture of schwann cells
Enriching and culturing of NF1 − / − Schwann cells from NF1-associated PN and normal human Schwan cells was done as described previously. 41 Cultures always contain at least some fibroblasts, and the Schwann cell component usually senesces by P8-P10, thus passages P4-P6 were used for most studies. Three cultures of normal human Schwann cells purchased from ScienCell Research Laboratories (Carlsbad, CA) were cultured the same way. One sample, PN9, required whole-genome amplification of both somatic and germline DNA.
Whole exome sequencing of matching pairs of tumor and normal DNA Exome capture of genomic DNA and library preparation for next generation sequencing was done by using Illumina TruSeq V1:32 and TruSeq V2:30 kits (62 Mb), per the manufacturer's instructions on 1 μg of tumor and matching normal genomic DNA. The sequencing was done on the Illumina HiSeq 2,500 system (Illumina, San Diego, CA, USA). Of 44 exomes, the average breadth of coverage was 89% (range 84-92%); the average depth of coverage was 59X (range 34-108X).
RNA extraction, Illumina whole transcriptome sequencing and Gene Set Enrichment Analysis (GSEA) RNA extraction and Illumina RNA sequencing was done as described previously. 42 RNA-Seq libraries were constructed from 1 μg total RNA after rRNA depletion using Ribo-Zero GOLD (Illumina). The Illumina TruSeq RNA Sample Prep V2 Kit was used according to manufacturer's instructions except where noted. The data were processed using RTA v. 1.18.64 and CASAVA v. 1.8.2. The data for 23 PN and two normal adult Schwann cells samples were further processed using standard Tuxedo pipeline. 43 The resulting gene expression from transcriptome datasets were then log2 transformed and standardized (z-scored). Genes with the median log2 FPKM score below 0.5 in both groups (PN and normal Schwann cells) were considered unexpressed and removed from the analysis. The resulting expression set of 11 293 genes was analyzed with GSEA as described. 44 We used 5000 permutations and shuffled the expression dataset by gene-sets rather than by sample labels. Gene-sets with FDRo0.01 were considered statistically significant and with 0.01 ⩽ FDRo 0.02 as trending.
Copy number variation and loss of heterozygosity CNV and LOH analyses were performed as described previously. 45 SNP genotyping was performed using HumanOmni2.5-8 BeadChip kits (Illumina) as per the manufacturer's instructions.
Non-NF1 somatic mutation verification and deep NF1 mutation detection by Ampliseq/IonTorrent Multiplex PCR primers for somatic mutation verification were designed using the Ion Ampliseq Designer tool (v.3.0.1, Life Technologies, Grand Island, NY, USA). Multiplex PCR amplification, library preparation and sequencing on the Ion Proton sequencer (Life Technologies) were performed as per the manufacturer's instructions. Reads from the Ion Torrent Proton sequencer were filtered, and adapter-and quality-trimmed. The resulting sequences were aligned to human reference genome hg19 using TMAP (Life Technologies). Resulting BAM files were further aligned using The Genome Analysis Toolkit (GATK, http://www.nature.com/ng/ journal/v43/n5/full/ng.806.html ). For missense and nonsense mutations, NF1 cDNA was examined by reverse-transcription PCR (Superscript II, Invitrogen) using primers flanking the affected exon, followed by Sanger sequencing (ABI Big Dye 3) to screen for splicing errors.
Whole exome sequencing analysis
The data were processed with two pipelines ('NISC' and 'Broad') (Supplementary Figure S1A) and somatic mutations were identified by subtracting germline variants. Alternatively, somatic variants were called by MuTect 46 (Broad pipeline; Supplementary Figure S1B ). Potential causative genes were analyzed with driver-passenger software. 47 Select somatic mutations were verified by using AmpliSeq and IonTorrent sequencing of targeted PCR products. IonTorrent sequencing data were compared with WES data; mutations identified by both technologies in the same tumor samples were deemed 'high-confidence' variants. Given the importance of NF1 in the tumors, we included the entire coding part of the gene into the AmpliSeq/IonTorrent validation effort. The NISC pipeline included the following components: Novoalign, v.2.08.02 (Novocraft.com, Selangor, Malaysia) for read alignment to hg19; duplicate removal with samtools; 48 bam2mpg for genotype calling and calculation of the quality score most probable genotype 49 and ANNOVAR for functional annotation of genetic variants 50 (http://www.openbioinformatics.org/annovar/). The resulting data were formatted in VarSifter 51 format (http://research.nhgri. nih.gov/software/VarSifter/) for further filtering. The filtering was done as follows. First, all non-coding variants and the nucleotides whose genotypes were identical in both tumor and corresponding normal DNA were removed. Second, from the remaining coding somatic variants all sequence variants that had a quality score (most probable genotype) o10 either in tumor or normal DNA were removed.
The Broad pipeline included the following components: BurrowsWheeler Aligner v. 0.6.2-r126 52 for mapping fastq files to hg19; Picard (https://broadinstitute.github.io/picard/) for removing duplicates; The Genome Analysis Toolkit (GATK) v.2.4-9 53 for local realignment and base quality recalibration; and GATK UnifiedGenotyper (https://software.broad institute.org/gatk/) for calling point mutations and insertions-deletions. ANNOVAR was used for functional annotation of genetic variants. Additional filtering used custom Perl scripts to remove all non-coding, low quality (scoreo200) and common variants (1,000 Genomes and NHLBI Exome Sequencing Project variant frequency40.01) as well as variants with alternative allele frequency below 0.3. In addition, MuTect 46 was used to compare tumor with matched normal DNA and identify somatic point mutations.
In both pipelines, variants of interest were referenced against the Human Gene Mutation Database (HGMD: www.hgmd.cf.ac.uk), Exome Aggregation Consortium (ExAC: http://exac.broadinstitute.org/), and the Catalog of Somatic Mutations in Cancer, (COSMIC: http://cancer.sanger.ac.uk/cosmic).
Passenger/driver analysis
We used the Youn and Simon ('NCI_DPS') software developed at NCI 47 or MutSigCV (http://www.broadinstitute.org/cancer/cga/mutsig). The NCI software was used with both the NISC and Broad pipelines whereas MutSig was used only with the Broad pipeline. To prepare data for MutSigCV, predicted somatic mutations from the 23 PN were first converted to MAF format using the UCSC 'known gene' annotations, 54 assigning an effect value of 'nonsilent' if a mutation altered the protein sequence for any of the annotated transcripts of a gene, 'silent' if the mutation resided within the coding sequence of a gene, and 'flank' if otherwise. Gene coverage, broken down by effect value, was evaluated similarly, making the assumption that a genomic position was 'covered' if both the tumor and the normal sample had adequate sequencing depth to genotype both samples with an most probable genotype score of 10 or greater. 49 For gene mutability covariate values, we used expression, replication time, and chromatin state values reported previously. 55 Coverage, MAF, and covariate files were then used as input to MutSigCV version 1.3.01 56 via the Broad Institute's GenePattern server. 57 Allele-specific copy number and LOH analysis of PN Paired CNV and LOH analysis of tumor and matching normal DNA was performed by using Nexus v.6.1 software (BioDiscovery Inc., Hawthorne, CA, USA) as described previously. 45 The analysis settings were selected based on the developer's suggestions for the analysis of tumor samples. 'Allele-Specific Copy number Analysis of Tumors' (ASCAT v.2.1) analysis was performed as previously described. 58 The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government.
